Redhill Biopharma Ltd RDHL Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.50 up $0.01, 2.65% at close Oct 15
Last close · Previous close $0.49
- Market cap
- At the Oct 15 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.50up $0.01, 2.65%Thu, Oct 15 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.49Oct 14
- Volume59.43KOct 15 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume885.29KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.44 to $2.14; now $0.50
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 15 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
RDHL trailed the S&P 500 in all 7 periods.
| Period | RDHL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RDHL: down 13.2% S&P 500: up 2.2% | RDHL trailed the S&P 500 by 15.4 percentage points Trailed |
| 3M | RDHL: down 32.8% S&P 500: up 2.5% | RDHL trailed the S&P 500 by 35.3 percentage points Trailed |
| YTD | RDHL: down 51.5% S&P 500: up 14.1% | RDHL trailed the S&P 500 by 65.6 percentage points Trailed |
| 1Y | RDHL: down 68.6% S&P 500: up 17.3% | RDHL trailed the S&P 500 by 85.9 percentage points Trailed |
| Long term | ||
| 3Y | RDHL: down 93.8% S&P 500: up 85.5% −60.3% vs +22.9% a year | RDHL trailed the S&P 500 by 179.3 percentage points Trailed |
| 5Y | RDHL: down 100.0% S&P 500: up 85.1% −84.1% vs +13.1% a year | RDHL trailed the S&P 500 by 185.1 percentage points Trailed |
| 10Y | RDHL: down 100.0% S&P 500: up 324.3% −64.0% vs +15.6% a year | RDHL trailed the S&P 500 by 424.3 percentage points Trailed |
$10,000 invested in RDHL 10 years ago (Oct 14, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $42,434.
RDHL trailed the S&P 500 in all 7 periods.
| Period | RDHL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RDHL: down 13.2% S&P 500: up 1.9% | RDHL trailed the S&P 500 by 15.1 percentage points Trailed |
| 3M | RDHL: down 32.8% S&P 500: up 2.2% | RDHL trailed the S&P 500 by 35.0 percentage points Trailed |
| YTD | RDHL: down 51.5% S&P 500: up 13.2% | RDHL trailed the S&P 500 by 64.7 percentage points Trailed |
| 1Y | RDHL: down 68.6% S&P 500: up 16.0% | RDHL trailed the S&P 500 by 84.6 percentage points Trailed |
| Long term | ||
| 3Y | RDHL: down 93.8% S&P 500: up 78.9% −60.3% vs +21.4% a year | RDHL trailed the S&P 500 by 172.7 percentage points Trailed |
| 5Y | RDHL: down 100.0% S&P 500: up 73.1% −84.1% vs +11.6% a year | RDHL trailed the S&P 500 by 173.1 percentage points Trailed |
| 10Y | RDHL: down 100.0% S&P 500: up 262.1% −64.0% vs +13.7% a year | RDHL trailed the S&P 500 by 362.1 percentage points Trailed |
$10,000 invested in RDHL 10 years ago (Oct 14, 2016) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $36,214.
All-time high
$19,790.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Jan 7, 2013.
Stock splits
2
Latest: 1-for-25 on . Share counts adjust after each split.
Both splits
- 1-for-25
- 1-for-40
Valuation
Financials
About Redhill Biopharma Ltd
RedHill Biopharma Ltd. is a U.S. specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota ®, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq ®. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a Phase 2-ready proof-of-concept study for GLP-1 /GIP receptor agonist-associated GI intolerance, positive results from a first U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a Phase 2-ready study for Crohn's disease (based on RHB-104's positive U.S. Phase 3 Crohn's disease study results); and (iv) RHB-107 ( upamostat ), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and influenza and also targeting multiple cancer and inflammatory gastrointestinal diseases.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
RDHL news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
RDHL stock FAQ
What is RDHL stock’s price today?
Redhill Biopharma (RDHL) traded at $0.50 at the close on , up $0.01 (2.65%) from the previous close of $0.49. Over the past 52 weeks it has traded between $0.44 and $2.14.
If you invested $1,000 in RDHL 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in RDHL on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago and $314 if invested one year ago. Past performance doesn’t predict future returns.
Does RDHL pay a dividend?
Redhill Biopharma hasn’t paid a dividend in the last twelve months.
What is RDHL’s 52-week high and low?
Over the past 52 weeks RDHL has traded as low as $0.44 and as high as $2.14. At $0.50 at the close on , it is 76.7% below that high and 14.7% above the low.
What is RDHL’s all-time high?
RDHL’s highest closing price was $19,790.00 on , adjusted for stock splits. At $0.50 at the close on , it is 100.0% below that record.
Has RDHL stock ever split?
Yes, twice: 1-for-40 on ; 1-for-25 on .
How has RDHL stock performed?
Including dividends and measured to the close on , RDHL has returned −51.5% so far this year and −68.6% over the past year, and −100.0% over five years (−84.1% a year). Over the same periods the S&P 500, measured by SPY, returned +14.1%, +17.3% and +85.1%. Past performance doesn’t predict future returns.
What exchange does RDHL trade on?
Redhill Biopharma trades on the Nasdaq under the ticker symbol RDHL. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.